Prognostic value of EMT-circulating tumor cells in metastatic breast can-cer patients undergoing high-dose chemotherapy with autologous hematopoietic stem cell transplantation

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 369-380

  Mego, Michal ^a,c   Gao, Hui ^a   Lee, Bang Ning ^a   Cohen, Evan N ^a   Tin, Sanda ^a   Giordano, Antonio ^a   Wu, Qiong ^a   Liu, Ping ^a   Nieto, Yago ^a   Champlin, Richard E ^a   Hortobagyi, Gabriel N ^a   Cristofanilli, Massimo ^b   Ueno, Naoto T ^a   Reuben, James M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Autologous hematopoietic stem cell transplantation; Circulating tumor cells; Epithelial mesenchymal transition; High dose chemotherapy; Metastatic breast cancer

Indexed keywords

CARBOPLATIN; CD34 ANTIGEN; CD45 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; EPITHELIAL CELL ADHESION MOLECULE; ETOPOSIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; TRANSCRIPTION FACTOR; TRASTUZUMAB;

ADULT; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; OVERALL SURVIVAL; PHENOTYPE; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84880329544     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.5111     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics. CA Cancer J. Clin 2010; 60: 277-300.
2. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 2006; 12: 6403-6409.
3. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004; 351: 781-791.
4. Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 2008; 113: 2422-2430.
5. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 2000; 342: 525-533.
6. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005; 353: 793-802.
7. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3(7): 687-94.
8. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004; 64(23): 8604-12.
9. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011; 71(2): 603-13.
10. Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A et al. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)CD24(lo) cancer stem cell phenotype. Eur. J. Cancer 2011; 47(10): 1527-36.
11. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009; 11(4): R46.
12. Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat Rev Clin Oncol 2010; 7(12): 693-701.
13. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133(4): 704-15.
14. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 2003; 15: 740-746.
15. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int. J. Cancer 2012; 130(4): 808-16.
16. Montemurro F, Rondâon G, Munsell M, Smith TL, Donato ML, Gajewski JL et al. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol. Blood Marrow Transplant. 2003; 9: 330-340.
17. Giuliano M, Giordano A, Hsu L, Handy BC, Ueno NT, Andreopoulou E et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy. J. Clin. Oncol. 2010; 28 suppl: 15s.
18. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117(7): 927-39.
19. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010; 12(10): 982-992.
20. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005; 8(3): 197-209.
21. Montemurro F, Ueno NT, Rondón G, Aglietta M, Champlin RE. High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. Clin Breast Cancer 2000; 1(3): 197-209.
22. Pecora AL, Lazarus HM, Jennis AA, Preti RA, Goldberg SL, Rowley SD et al. Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance. Biol. Blood Marrow Transplant. 2002; 8(10): 536-43.
23. Cooper BW, Moss TJ, Ross AA, Ybanez J, Lazarus HM. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J. Clin. Oncol. 1998; 16(11): 3509-3517.
24. Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J. Clin. Oncol. 1996; 14(6): 1868-1876.
25. Weaver CH, Moss T, Schwartzberg LS, Zhen B, West J, Rhinehart S et al. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells. Bone Marrow Transplant. 1998; 21(11): 1117-1124.
26. Ho AD, Gluck S, Germond C, Sinoff C, Dietz G, Maruyama M et al. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 1993; 7(11): 1738-46.
27. Muller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino AE et al. Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol. Blood Marrow Transplant. 2012; 18(1): 125-33.
28. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82(9): 2605-10.
29. Syme R, Stewart D, Rodriguez-Galvez M, Luider J, Auer Y, Klassen J et al. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT). Bone Marrow Transplant. 2003; 32(3): 307-11.